Condition (MeSH)
Neurofibromatosis 2
ClinicalTrials.gov lists 47 trials for Neurofibromatosis 2 or a narrower condition beneath it. FDA Office of Orphan Products Development has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
47 of the 47 trials are tagged with Neurofibromatosis 2 itself; the rest are tagged with a narrower condition beneath it.
When did Neurofibromatosis 2 trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 4 |
| 2016 | 4 |
| 2015 | 2 |
| 2014 | 4 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neurofibromatosis 2 trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 3 |
| Phase 2 | 20 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 7 |
| Observational | 9 |
| Expanded access | 1 |
How many Neurofibromatosis 2 trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Completed | 25 |
| Terminated | 7 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neurofibromatosis 2 trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| FDA Office of Orphan Products Development | 2 |
Which drugs are being tested for Neurofibromatosis 2? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EVEROLIMUS | 4 |
| Selumetinib | 3 |
| LAPATINIB | 2 |
| Luvometinib | 2 |
| AR-42 | 2 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bevacizumab 1 | 5 |
| EC Aspirin | 1 |
| Trineumin | 1 |
| 2.0 aflibercept | 1 |
| Endostatin | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neurofibromatosis 2 trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 13 | 2 |
| Fatigue | 9 | 1 |
| Atrial fibrillation | 8 | 1 |
| Seizure | 8 | 3 |
| Syncope | 8 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Neurofibromatosis 2? (33)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. | Journal of neuro-oncology | 2024 | Yes |
| Brigatinib in <i>NF2</i>-Related Schwannomatosis with Progressive Tumors. | The New England journal of medicine | 2024 | Yes |
| Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents. | Journal of neuro-oncology | 2023 | Yes |
| Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial. | Journal of neuro-oncology | 2022 | Yes |
| A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. | Cancer chemotherapy and pharmacology | 2021 | Yes |
Showing 5 of 33 publications.
Prevalence (8)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Full NF2-related schwannomatosis | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Full NF2-related schwannomatosis | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Full NF2-related schwannomatosis | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Full NF2-related schwannomatosis | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Full NF2-related schwannomatosis | Prevalence at birth | 1-9 / 100 000 | Finland | Not stated | Exact |
Showing 5 of 8 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Full NF2-related schwannomatosis | 637 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Full NF2-related schwannomatosis | 637 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.